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The AMD (Associazione Medici Diabetologi)Annal initiative is an ongoing observational survey 
promoted by AMD. It is based on a public network of about 700 italian diabetes clinics, run by 
specialists who provide diagnostic confirmation and prevention and treatment of diabetes and its 
complications. Over the last several years, the analysis of the AMD Annals dataset contributed 
several important information on clinical features and their prognostic and therapeutic implications 
of type 2 diabetes kidney disease. Among these: (a) non-albuminuric renal impairment is the 
predominant clinical phenotype, although associated to a lower risk of progression as compared to 
overt albuminuria, it contributes significantly to the burden of end stage renal disease morbidity; (b) 
optimal blood pressure control provides significant but incomplete renal protection, it reduces 
albuminuria but there may be a J curve phenomen with eGFR at very low blood pressure values; (c) 
Hyperuricemia and diabetic hyperlipidemia, namely hypertriglycerides and low HDL cholesterol are 
strong independent predictor of chronic kidney disease  onset in diabetes, although the pathogenetic 
mechanisms underlying these associations remain uncertain; (d) long term intra individual variability 
in HbA1c, lipid parameters, uric acid and blood pressure plays a greater role in the appearance and 
progression of chronic kidney disease   than the absolute values of each one of these variables. These 
data help clarify the natural history of chronic kidney disease  in patients with type 2 diabetes and 
provide important clues to devise future interventional studies. 
 






Diabetes mellitus is the leading cause of chronic kidney disease (CKD). In fact, approximately 40% of 
patients with diabetes develop diabetic kidney disease (DKD) resulting in albuminuria, reduction of 
glomerular filtration rate (GFR), or both. The typical natural history of diabetic nephropathy has been 
derived mainly from longstanding epidemiologic studies in patients with type 1 diabetes mellitus (T1D). In 
these patients, microalbuminuria is the first sign of renal impairment and may progress to macroalbuminuria, 
which predicts subsequent decline of GFR and, eventually, end stage renal disease (ESRD). The natural 
history of DKD in type 2 diabetes mellitus (T2D) appears to be more heterogeneous. In fact, several studies 
have recently shown that a majority of patients with DKD may progress to ESRD despite having modest or 
no albuminuria [1-3].
Since its early stages, CKD is also associated with an increased risk of death, particularly from 
cardiovascular disease (CVD). The presence of a mild or moderate renal impairment entails a risk for 
cardiovascular (CV) complications and death that has been shown to be even greater than progression to 
ESRD in some [4], although not all studies [5].  Both features of DKD, albuminuria and reduced GFR values 
have independent prognostic values in terms of CV and renal outcome [6].  
It is therefore of paramount importance to detail natural history of different renal phenotypes and their 
prognostic implications in patients with T2D. 
Here, we report a summary of recent studies from the AMD (Associazione Medici Diabetologi) Annals 
initiative that have provided important information on presenting clinical features and their prognostic and 
therapeutic implications in a very large cohort of Italian patients with T2D. 
 
The AMD annals initiative  
In Italy, diabetes care is mainly provided by a public network of about 700 diabetes clinics, run by specialists 
who provide diagnostic confirmation and prevention and treatment of diabetes and its complications through 
close patient follow-up and regular check-ups [7]. The Italian AMD Annals initiative has been devised to 
analyze the AMD database and identify a set of indicators that can be used in the context of continuous 
quality improvement. Participating centers adopted the same software system for the everyday management 
of outpatients, while a specially developed software package allowed for extraction of specific information. 
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Data from all participating centers were collected and centrally analyzed anonymously. T2D was diagnosed 
at participating diabetes centers according to the American Diabetes Association 2003 criteria. The 
biochemical measurements were performed at clinical laboratories at each participating center. This initiative 
includes measuring and monitoring renal function (creatinine, uric acid and albuminuria), hemoglobin A1c 
(HbA1c), blood pressure (BP) and lipid profile (LDL cholesterol or total and HDL cholesterol and 
triglycerides). The use of specific classes of drugs (insulin, oral antidiabetic, statins, antihypertensive agents) 
was also evaluated. Because normal ranges for HbA1c varied among centers, the percentage change with 
respect to the upper normal value (measured value/upper normal limit) was estimated and multiplied by 6.0 
to allow comparisons among the centers. Kidney function was assessed by serum creatinine and urinary 
albumin excretion measurements. GFR was estimated  (eGFR) for each patient using a standardized serum 
creatinine assay and the CKD-Epidemiology Collaboration equation [8]. Increased urinary albumin excretion 
was diagnosed and defined as albuminuria if urinary albumin concentration was >30 mg/L, urinary albumin 
excretion rate was >20 mg/min, or urinary albumin-to-creatinine ratio was >2.5 mg/mmol in men and >3.5 
mg/mmol in women. CKD was defined as albuminuria or low eGFR (<60 ml/min/1.73m2 per 1.73 m2) or 
both. There are both weaknesses and strengths that should be kept in mind when interpreting study results. In 
fact, the AMD Annals initiative, does not make use of a central laboratory and this may have led to some 
degree of variability in laboratory results. Although creatinine determination cannot always be referred to 
IDMS procedures, most laboratories around the country currently use the Jaffè method, which has been 
shown to have good reproducibility. In addition, information on albuminuria were available only as a 
categorical trait. On the other hand,  the study has several strengths since the large size of the database and 
the homogeneous geographical distribution of participating centres provide a realistic snapshot of real life 
clinical situation representative of the Italian health care system. 
 
Natural history of diabetic renal disease  
DKD phenotypes and related risk factors were investigated in a large cohort of T2D patients (n= 120.903) 
with a mean age of 66.6 ± 11.0 years, 58.1% male and a mean duration of diabetes of 11.1 ± 9.4 years, the 
proportion of patients with albuminuria was 36%, while low GFR was found in 24% and both albuminuria 
and low GFR in 12% of patients [7]. It is noteworthy that out of 28.806 patients with low eGFR (i.e. <60 
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ml/min/1.73m2), 13.660 (48%) had an isolated reduction of GFR (i.e. normoalbuminuric renal impairment). 
In our series, diabetic patients with isolated reduction of GFR were more often females, showed similar age, 
shorter duration of diabetes, higher GFR and HDL cholesterol, and lower HbA1c, systolic BP and 
triglycerides as compared to patients with both low GFR and albuminuria.  Although observational data 
such as these cannot provide conclusive information and should be considered as hypothesis-
generating, our study suggests that reduced eGFR and albuminuria, showing at least in part, distinct 
sets of clinical correlates, might therefore entail different pathogenetic mechanisms.  
Moreover, the AMD Annals Initiative provided an opportunity to describe that CKD components, mainly 
high albuminuria, are associated with failure to reach therapeutic targets, especially for HbA1c and BP, 
despite a greater use of drugs in patients with T2D [9].  In contrast with T1D, where albuminuria usually 
precedes and predicts renal function deterioration, in patients with T2D increased albuminuria carries a less 
specific predictive power with respect to renal function worsening [10]. It has recently been reported that a 
significant portion of T2D diabetic patients may eventually progress toward ESRD even in the absence of 
increased albuminuria [11]. In the Nefron study, more than half of patients with Type 2 diabetes had urinary 
albumin excretion rate persistently in the normal range, although renal impairment in the absence of 
albuminuria was less common in those with diabetes than in the general population [1]. Based on the rising 
trend in the prevalence of diabetes, it has been suggested that more studies are needed to clarify the 
pathogenesis, prevention, and treatment of nonalbuminuric renal impairment, which is, in reality, the most 
common cause of renal impairment in the western world. 
To address this issue 17,160 T2D patients with baseline eGFR value >60 ml/min/1.73m2. were prospectively 
studied over a 4-year follow-up. Baseline albuminuria was equally distributed among patients with eGFR 
values above and below 90 mL/min/1.73m2 (22.3% and 22.7%, respectively). When compared to patients 
with eGFR >90 mL/min71,73m2 and normoalbuminuria [12], the OR of developing the composite renal 
endpoint over the 4-year study period was 1.67 for patients with albuminuria and baseline eGFR values 
above 90 mL/min/1.73m2 and rose progressively to 2.9 in patients with normoalbuminuria and GFR values 
between 90 and 60 mL/min/1.73m2 and then further up to 5.2 when albuminuria was concomitant with mild 
GFR reduction (i.e. GFR between 90 and 60 mL/min/1.73m2). At any given level of GFR, the concomitant 
presence of albuminuria entails an elevated renal risk, although even modest reductions in GFR (e.g. 5 
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mL/min/1.73m2) seem to confer a significantly greater renal risk in the long term. This translates into a 
greater absolute number of non-albuminuric as compared to albuminuric patients progressing to stage 3 CKD 
over a four-year follow-up. In fact, two third of those patients reaching eGFR below 60 ml/min/1.73m2 
showed no albuminuria at baseline. 
 
Hypertension and renal risk  
Antihypertensive treatment and BP reduction are known to retard the progression of 
CKD in T2D but long-term real-life clinical data on the incidence of DKD are lacking. The AMD annals 
database provides a unique opportunity to perform an observational, prospective cohort study, investigating 
the association between achievement and maintenance of recommended BP values and the incidence of 
DKD and its components. To this purpose, clinical records from a total of about 13,000 patients with normal 
renal function and normal urine albumin excretion at baseline and with regular visits during a 4-year follow-
up were retrieved and analyzed [13]. The relationship between recommended, time-updated BP control 
(BPC) (i.e. ≥75% of visits with SBP and DBP <140/85 mmHg) and the incidence of renal outcomes was 
evaluated. At baseline, 28% of patients (n=3612) had recommended BP values. Over the follow-up period, 
37% developed DKD, 16% low GFR and 27% albuminuria. Patients who failed to achieve and maintain 
BPC over the study period showed an increased risk of developing DKD [odds ratio (OR) 1.38, P<0.001], 
low GFR (OR 1.18, P.0.03) and albuminuria (OR 1.47, P<0.001) as compared with those with persistent 
BPC. These results were confirmed after adjustment for confounders and in different subgroups. 
This large, real-life cohort study shows that achieving and maintaining BP values below 140/85 mmHg is 
associated with a significant reduction in the incidence of CKD and its components in patients with 
hypertension and T2D over a 4-year follow-up. However, despite optimal BP reduction, residual renal risk 
remains high in patients with T2D and hypertension (Figure 1). 
In a different study, the predictive role of changes in albuminuria on the loss of renal function under 
antihypertensive treatment was investigated on a total of 12 611 hypertensive T2D patients with normal 
eGFR at baseline over a 4-year period [14]. The association between changes in albuminuria status during a 
1-year baseline period and time updated BP and eGFR loss overtime was assessed. Mean age at baseline was 
65±9 years, known duration of diabetes11±8 years, eGFR 85±13 ml/min/1.73m2 and BP 142±17/81±9 
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mmHg. Patients with persistent albuminuria showed the highest 4-year risk of eGFR loss more than 30% 
from baseline or onset of stage 3 CKD (eGFR<60 ml/min/1.73m2) as compared with those with persistent 
normal albuminuria (odds ratio 2.00, confidence interval 1.71–2.34; P<0.001). Female gender, disease 
duration, age, BMI, lipid profile, low baseline eGFR, the number of antihypertensive drugs and variations in 
albuminuria status were relatated with renal risk in the whole study population. Furthermore, lower time 
updated BP values and the use of RAAS- inhibitors were asssociated to the development of renal endpoints 
only in patients without albuminuria. The study shows that under real-life clinical conditions, changes in 
albuminuria parallel changes of renal risk. Thus, albuminuria status could be a guide to optimize therapeutic 
strategy. Reduction of albuminuria or its prevention should be sought to maximize renal protection in T2D 
with hypertension (Figure 2). Furthermore, in the absence of albuminuria less strict BP target could be 
advisable and RAS-i may not necessarily represent the preferred antihypertensive drug. An individually 
tailored strategy both in terms of BP reduction and type of antihypertensive agents could be desirable 
depending on the presenting renal phenotype. This issue deserves to be further investigated by adequately 
powered RCTs conducted in patients with nonalbuminuric renal impairment. 
Another important clinical issue in T2D patients at high renal risk is the presence and prognostic impact of 
apparent treatment resistant hypertension (aTRH).  Resistant hypertension has been defined as failure to 
achieve recommended blood pressure levels despite concurrent use of three antihypertensive agents of 
different classes including a diuretic. TRH is becoming an increasingly frequent challenge in clinical 
practice, in light of current guidelines recommendations favoring more ambitious therapeutic targets in high 
risk patients. To investigate this issue, clinical records from a total of 29 923 patients with T2D and 
hypertension, with normal baseline eGFR and regular visits during a 4-year follow-up, were retrieved and 
analyzed [15]. The association between time-updated BP control (ie, 75% of visits with BP <140/90 mm Hg) 
and the occurrence of eGFR <60 ml/min/1.73m2 and/or a reduction ≥30% from baseline was assessed. At 
baseline, 17% of patients had aTRH. Over the 4-year follow-up, 19% developed low eGFR and 12% an 
eGFR reduction ≥30% from baseline. Patients with aTRH showed an increased risk of developing both renal 
outcomes (adjusted odds ratio, 1.31 and 1.43; P<0.001 respectively), as compared with those with non-
aTRH. No association was found between BP control and renal outcomes in non-aTRH, whereas in aTRH, 
BP control was associated with a 30% (P=0.036) greater risk of developing the renal end points. Thus, it 
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appears that under real-life conditions in patients with T2D and hypertension the presence of aTRH entails a 
significantly greater risk of developing CKD and/or a clinically relevant reduction in eGFR. The 
achievement and maintenance of recommended BP values (ie, 75% of visits with BP <140/ 90 mm Hg) are 
associated with a worse renal outcome in aTRH patients. The relationship between achieved BP and renal 
function seems to be J-shaped, at least at very low levels, with optimal SBP values between 120 and 140 mm 
Hg (Figure 3). There is a need for early identification and management of patients to prevent the 
development of aTRH and associated increase in renal morbidity. Reduction of antihypertensive treatment 
should be considered in a small, but relevant, proportion of patients in order to improve renal outcome. A 
similar study was also conducted in a cohort of 2,778 diabetic patients with hypertension and stage 3 CKD at 
baseline to  assess the role of aTRH and time-updated BP control (BPC) on the progression of CKD [16]. 
Apparently TRH was present in 33% of patients at baseline. Over the 4-year follow-up, 20% of study 
patients developed an eGFR reduction >30%, with the aTRH subgroup showing an increased risk  of 
reaching this endpoint (OR 1.31; P<0.007). Furthermore, in patients with aTRH, BPC was associated with a 
79% (P=0.029) greater risk of eGFR reduction despite a 58% (P=0.001) lower risk of albuminuria status 
worsening. In non-aTRH, no association was found between renal outcome and BPC.  In patients with aTRH, 
the loss of eGFR over a four-year follow-up period was faster and achievement and maintenance of 
recommended BP values is associated with a worse renal prognosis despite greater albuminuria reduction. 
Thus, aTRH seems to be associated with a burden of risk modifiable only in part by BP reduction. Further 
studies are clearly needed to investigate the pathophysiological mechanism underlying the effect of BP 
reduction per se as well as different pharmacologic strategies on renal outcome in high risk hypertensive 
patients such as those with diabetes and CKD. 
 
 
Uric acid and the metabolic syndrome  
A hotly debated and currently unresolved issue is the role of serum uric acid (SUA) in the development of 
DKD. Several cross-sectional observational studies have documented a strong association between increased 
SUA levels and reduction of GFR or albuminuria in patients with T2D. Indeed, some studies have yielded 
conflicting results, mainly after adjustment for confounders. We prospectively explored the association of 
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SUA and incident CKD in a large cohort of patients with T2D with preserved renal function at baseline. We 
found a strict correlation at 4-year follow up between SUA and DKD (i.e. eGFR < 60 ml/min/1.73m2) with a 
progressive and constant increased of patients who develop low eGFR from second to fifth quintile of 
baseline SUA values, also after adjusting for several variables, such as BP, BMI, glycometabolic control, and 
lipid profile [17]. The association between SUA with the incidence of albuminuria appeared to be weaker, 
with albuminuria increased only in the fifth quintile of baseline SUA levels (Figure 4). In addition, the 
duration of diabetes appeared to be a modulator of the link between SUA and incident of DKD being it 
weaker in patients with short disease duration. In conclusion, results of our study strongly suggest a 
causative role of UA in DKD in patients with T2D. 
It is well known as hyperuricemia (HU) is strongly associated with metabolic syndrome (Mets) and its 
individual components, even after adjusting for obesity and Insulin Resistance (IR). Being both UA and 
Mets predictors of DKD, in another study we sought to dissect whether they contribute to the onset of DKD 
independently of each other. We found that, after adjustment for confounders such as high BP, high 
triglycerides low HDL, HU remained independently associated to the development of DKD [18]. In addition, 
the incidence of low eGFR was higher in patients with HU also when the coexistence or absence of Mets 
was taken into account, while albuminuria developed more frequently in those with HU and Mets as 
compared to the group of reference.  
Taken all together these results highlight the harmful role of both SUA and Mets and their potential 
interaction on kidney and may be relevant to help focusing on better prevention and therapeutic strategies of 
kidney damage in patients with T2D. Randomized controlled trials will further clarify the effect of SUA 
lowering treatment on DKD risk. A multicenter randomized, placebo-controlled study, Prevention of Early 
Renal function Decline (PERL), is currently investigating the effect of SUA lowering by allopurinol in 
patients with T1D [19]. No information is available about such a trial in patients with T2D.   
 
Diabetic dyslipidemia  
In spite of the adequate control of traditional DKD risk factors including LDL cholesterol as recommended 
by international guidelines, the occurrence of DKD remains high in T2D patients. Several studies indicate 
that diabetic dyslipidemia, i.e. high triglycerides (TG) and/or low high density lipoprotein cholesterol (HDL-
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C)  levels, has been consistently shown to be an independent residual risk for DKD in patients with at-target 
values of blood glucose and BP.  Although the pathophysiological bases linking dyslipidemia to DKD are 
still largely undefined,  it has been  suggested that either deficient and/or dysfunctional HDL particles, 
hampering reverse cholesterol transport from renal cells,  may contribute to intra-renal lipid accumulation 
leading to glomerulosclerosis and tubule-interstitial damage [20]. On the other hand, high TG/low HDL-C is 
the typical lipid pattern of insulin-resistant states and  it is plausible that this metabolic derangement in T2D 
facilitates the  toxic effects of accumulated lipids on the kidney microvascular bed [21-24]. In the large 
cohort of T2D subjects at high cardiovascular risk participating to the ADVANCE (The Action in Diabetes 
and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation Study) Study, after 5 years of 
follow-up, HDL-C levels in the lowest tertile were associated with a 19% higher risk of DKD risk than those 
in the highest tertile (OR 1.19 ; 95% CI 1.08-1.32, P = 0.0005) [25]. In another prospective study including ~ 
900 T2D subjects,  TG/HDL-C ratio was positively associated with the composite end-point of retinopathy 
and nephropathy, independently  from LDL-C, HbA1c, smoking, hypertension and other variables [26]. The 
results of the RIACE (Renal Insufficiency And Cardiovascular Events) study demonstrating an independent 
association of high TG levels with  DKD [27], and the  slow-down of GFR decline and albuminuria with 
fenofibrate [3] are in line with these results.  
To further investigate this issue, data collected from a large cohort of  >15,000 DKD-free T2D subjects, with 
controlled LDL-C values at baseline, participating in the AMD Annals Initiative were analyzed 
longitudinally over a 4-year follow-up period [28]. Overall, 32% of study subjects developed DKD during 
study period,  23.2% developed albuminuria, 19%  low eGFR values or eGFR decline >30%,  and 4% of 
them developed both renal abnormalities. Notably, after controlling for LDL-C levels and  a large set of 
potential confounding risk factors, the occurrence and progression of these renal abnormalities were 
significantly associated  with out-of target baseline TG and/or  HDL-C levels: TG levels ≥150 mg/dl  
increased the risk of albuminuria by 19%, of low GFR by 26%, of eGFR decline by 29%, and of developing 
low eGFR or albuminuria by 35% ; the risk of developing albuminuria associated with low HDL-levels was 
24% and that of developing low eGFR and/or albuminuria was 44%, with linear trend of the risk with 
increasing TG or decreasing HDL-C values (Figure 5). Several other smaller epidemiological studies have 
also pointed to the role of diabetic dyslipidemia as risk factor for incidence and progression of DKD, 
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whereas other Authors did not confirm its independent association with microangiopathy [29-31].  These 
controversial results may depend upon several factors, including the modulating effect of gender and/or 
genetic background on these associations. Clearly, further interventional studies are warranted to explore the 
possibility of improving renal outcome by targeting lipid metabolism and especially triglycerides levels in 
T2D patients. 
 
Risk factors variability  
 
Targeting HbA1c reduces the risks of micro- and macrovascular complications. However, glycaemic 
variability, more deleterious on endothelial cells than stable high glucose levels, has been associated with 
diabetes vascular complications both in epidemiological as well as experimental studies [32-33]  even in 
subjects with at -target HbA1c values [34]. Long-term glycemic variability, which refers to variations of 
HbA1c levels over several weeks or months, has been associated with the risk of developing long term 
complications, including DKD.  Notably, a recent meta-analysis  reported that HbA1cvariability is a risk 
factor for renal disease in both  T1D and T2D [35], being associated, in T2D individuals,  with a higher risk 
of renal disease (1.34 [1.15–1.57]), as well as of macrovascular events, ulceration/gangrene, cardiovascular 
disease and mortality. 
Data on the role of glycaemic variability on DKD have been reported both in the ADVANCE [36] in the 
RIACE study [37], and in the DCCT study [38] with not completely overlapping results.  Also BP variability 
has been associated with vascular complications [39], and increasing evidences suggest that also BP and 
HDL-C variability may be related to the development of  DKD in T2D. On the other hand, risk factors 
variability may also be the expression of the variability in the quality of care/efficacy of treatments that may 
be associated with poorer outcomes. While, it is logical to hypothesize that long-term variability in major 
risk factors for DKD, i.e. glucose, BP and lipid control may have an impact on its occurrence and 
progression, data on the possible interaction between the variability of all these risk factors on both the 
development of albuminuria and GFR decline in T2D are still sparse. 
These issues were explored in the AMD database by looking at the correlation between intra-individual 
variability in lipid parameters, serum UA, HbA1c, BP, and the incidence of albuminuria or CKD [40]. All 
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patients with at least five measurements of the following parameters (HbA1c, SBP and diastolic BP (DBP), 
serum UA, total cholesterol, HDL, LDL and triglycerides) recorded over a period of 3 consecutive years 
were identified and those patients with normal albuminuria or a GFR ≥60 mL/min/1.73 m2 were followed-up 
for up to 5 years (longitudinal phase). It was found that lipid, UA, BP and HbA1c variability might have 
different impact on the development of CKD components in T2D. 
Variability in HbA1c was associated with a significantly higher risk of developing albuminuria  [upper 
quartile hazard ratio (HR) = 1.3; 95% confidence interval (CI) 1.1-1.6]. Variability in UA, LDL-C, HDL-C, 
systolic and diastolic BP,predicted the decline in eGFR, the association with UA variability being the 
strongest (upper quartile HR = 1.8; 95% CI 1.3-2.4).  Moreover, the application of RECPAM techniques 
allowed for the identification of distinct subgroups showing a different likelihood of developing DKD 
features. Five subgroups, characterized by an increased risk of developing albuminuria and GFR decline, 
were identified by RECPAM. The concomitance of an increased variability in HbA1c and HDL-C conferred 
the highest risk of developing albuminuria (HR = 1.47; 95% CI 1.17-1.84), while variability in UA (HR = 
1.54; 95% CI 1.19-1.99) or DBP (HR = 1.47; 95% CI 1.11-1.94) conferred the highest risk of decline in 
eGFR (Figure 6).  Furthermore, data showed that HbA1c variability exerts a greater impact on the 
appearance of albuminuria than on the decline of GFR, which is consistent with a previous report., The most 
intriguing data from RECPAM analysis has to do with renal function, and indicates that UA variability is the 
strongest risk factor for GFR decline with the significant contribution of concomitant BP variability.  
 
Conclusions 
CKD remains a feared complication of T2D and its prevention and treatment is a therapeutic challenge, 
despite achievement of recommended therapeutic targets.  The AMD database provides unique opportunities 
to characterize disease natural history and therapeutic  issues under real life clinical conditions in Italy.  
Recent studies, from the AMD Annals group emphasize the high prevalence/incidence  of DKD, the growing 
figure of non albuminuric renal presentation, the role of traditional (BP, AlbU) and emerging risk predictor 
(TG, SUA, long term variability). While there is growing expectations on the CV and renal effects of 
recently developed glucose lowering drugs, glucose and BP control, together with RAAS-I remain the 
cornerstones of treatment. Over the next few years, further, well performed real-life clinical studies will be 
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helpful to integrate results of RCTs in the assessment of therapeutic advances for people with diabetes at 
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Fig. 1 Blood pressure status and the incidence of chronic kidney disease in patients with hypertension 
and T2D 
Blood pressure control indicates patients with over 75% of BP values <140/85 mmHg over a 4 year follow-
up period (Modifiied from ref 13) 
 Fig. 2 Changes in albuminuria and renal outcome in patients with hypertension and T2D 
Four year cumulative incidence of the combination of estimated glomerular filtration rate reduction more 
than 30% from baseline and onset of eGFR less than 60 ml/min/1.73m2 in study patients stratified on the 
basis of albuminuria status 
eGFR, estimated glomerular filtration rate. NN, Sustained normoalbuminuria; N-AlbU, Progression to 
albuminuria;  AlbU-N, Remission to normoalbuminuria; AlbU-AlbU, Persistent albuminuria (Modifiied 
from ref 14) 
 Fig. 3 The J curve relationship between blood pressure and renal function 
Odds ratios with 95% confidence interval of reaching renal end point (eGFR <60 mL/min per 1.73 m2) on 
the basis of time-update mean SBP in patients with T2D and treatment resistant hypertension (aTRH), taking 
140 mm Hg in non aTRH patients as reference category. Patients were grouped into 10 mm Hg subsets. The 
subset of patients with No-aTRH and 140 mm Hg SBP was taken as the reference group. 
ATRH indicates apparent treatment resistant hypertension; eGFR, estimated glomerular filtration rate 
 Fig. 4 Odds ratio for new onset renal damage by gender specific serum uric acid quintiles 
* p< 0.001;  vs I gender specific quintile (Modifiied from ref 15) 
 Fig. 5 Plasma triglycerides (>150 mg/dl) predict the development of diabetic kidney disease in subjects 
with type 2 diabetes: the AMD Annals initiative 
(Modifiied from ref 17)  
Fig. 6 Recursive partitioning techniques (RECPAM) analysis of developing albuminuria (A) and 
eGFR <60 (B)  
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The RECPAM tree-growing algorithm models the hazard of developing GFR<60 ml/min/1.73 m2 or 
albuminuria during follow-up for up to 5 years based on a multivariable Cox regression analysis. At each 
partitioning step, the method selects the covariate with the binary split that maximizes the difference in risk. 
The algorithm stops when user-defined conditions (stopping rules) are met. The minimum set considered in 
our analysis comprised 50 cases of GFR declineor albuminuria incidence and 250 patients per node. Splitting 
baseline variables were quartiles of variability in HbA1c, systolic blood pressure (SBP) and diastolic blood 
pressure (DBP), serum uric acid, total, HDL, LDL cholesterol and triglycerides. The following baseline 
variables were included in the model as global variables: age, gender, duration of diabetes, smoking, 
hypertension, baseline HbA1c, blood pressure, presence of albuminuria, serum uric acid, lipid parameters 
and eGFR values. Values associated with patient assignment to each of the 2 subgroups (circles or 
rectangles, the latter representing final RECPAM classes) are shown on the branches leading to the 
subgroup. The data in the circles and rectangles represent the ratios of the number of patients who develop 
GFR<60 ml/min/1.73 m2 or albuminuria, respectively, to the total number of patients in the subgroup 
(Modifiied from ref 40) 
 
 
 
